Information about Alfuzosin
Alfuzosin is a nonselective alpha-1 adrenergic antagonist used in the therapy of benign prostatic hypertrophy.
Liver safety of Alfuzosin
Alfuzosin is associated with a low rate of transient serum aminotransferase elevations and with rare instances of clinically apparent acute liver injury.
Mechanism of action of Alfuzosin
Alfuzosin (al fue' zoe sin) is an alpha-1 adrenergic antagonist approved for use in the United States for benign prostatic hypertrophy (but not for therapy of hypertension). Alfuzosin inhibits alpha adrenergic receptors present on smooth muscle in arterioles (called alpha-1b adrenergic receptors), as well as in those in the bladder neck and prostate (alpha-1a adrenergic receptors). The effects of the agent on smooth muscle of the bladder and prostate causes improvement in urine flow in men with partial obstruction due to benign prostatic hypertrophy.
FDA approval information for Alfuzosin
Dosage and administration for Alfuzosin
Alfuzosin is available in extended release tablets of 10 mg in several generic forms and under the trade name Uroxatral. The recommended dose is 10 mg with the same meal once daily.
Side effects of Alfuzosin
Side effects include hypotension, dizziness and syncope (particularly with the initial dose), fatigue, headache, dizziness, palpitations, impotence, incontinence and gastrointestinal upset. Rare, but potentially severe adverse events include postural hypotension, worsening of angina pectoris, priapism and intraoperative floppy iris syndrome. Alpha-blockers used to treat benign prostatic hypertrophy (BPH):
5-Alpha Reductase Inhibitors